期刊文献+

替罗非班对非ST段抬高急性冠脉综合征肥大细胞类胰蛋白酶的影响

下载PDF
导出
摘要 目的观察替罗非班对非ST段抬高急性冠脉综合征(NSTE-ACS)患者血清肥大细胞类胰蛋白酶(MCT)的影响。方法将NSTE-ACS患者45例,随机分为两组,常规治疗组应用阿司匹林、氯吡格雷、低分子肝素治疗;替罗非班治疗组在常规治疗的基础上加用替罗非班。观察两组患者治疗前及治疗后6 h、24 h血清MCT的变化。结果替罗非班组血清MCT浓度在治疗后24h较治疗前降低(P<0.05);治疗后6 h与治疗前及治疗后24 h比较差异均无统计学意义(P>0.05)。常规治疗组血清MCT浓度在治疗前、治疗后6 h及治疗后24 h比较差异均无统计学意义(P>0.05)。结论替罗非班可以降低NSTE-ACS患者血清MCT的含量,有利于动脉粥样硬化斑块的稳定。
出处 《中西医结合心脑血管病杂志》 2011年第8期1007-1009,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
  • 相关文献

参考文献11

  • 1高明明,孙吴,何冀芳.非ST段抬高急性心肌梗死//王乐非.急性冠脉综合征.北京:人民卫生出版社.2009:200-219.
  • 2林运灵,陈良龙.肥大细胞与缺血性心脏病[J].心血管病学进展,2007,28(2):215-218. 被引量:2
  • 3陆再英,钟南山.内科学[M].北京:人民卫生出版社,2007.26.
  • 4王建玲,王敬萍,王日军.替罗非班治疗非ST段抬高型急性冠状动脉综合征的临床观察[J].中国药物与临床,2010,10(1):77-78. 被引量:14
  • 5Lina B,Gemma V. Coronary atherothrombotic disease progress in antiplatelet therapy[J]. Rev Esp Cardiol, 2008,61 :501 - 513.
  • 6Robert AH, Richard CB. Christopher PC, et al. Antithrombotic therapy for Non - ST - Segment elevation acute eoronary syn dromes[J]. Chest, 2008,133 : 670S - 707S.
  • 7Nerea V,James A,Peter L,et al. Soluble CD40L risk prediction af- ter acute coronary syndromes [J]. Circulation, 2003, 108:1049 - 1052.
  • 8Ilze B, Saskia CA, de Jager,et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipopro- tein E - deficient mice[J]. Circulation, 2007,115 : 2516 - 2525.
  • 9Wang Y, Shiota N, Leskinen MJ, et al. Mast cell chymase inhibits smooth muscle cell growth and collagen expression in vitro:Trans- forming growth factor - beta1 - dependent and - independent effects[J]. Arterioscler Thromb Vasc Biol; 2001,21 :1928 - 1933.
  • 10Blair RJ, Meng H, Marchese MJ, et al. Human mast cells stimu- late vascular tube formation. Tryptase is a novel, potent angiogen- ic factor[J]. J Clin Invest, 1997,99 : 2691 - 2700.

二级参考文献61

  • 1高明明,孙吴,何冀芳.非ST段抬高急性心肌梗死//王乐非.急性冠脉综合征.北京:人民卫生出版社.2009:200-219.
  • 2Harrington RA,Backer RC,Cannern CP, et al. Antithrombotic therapy for Non-ST-segment elevation acute coronary syndromes. Chest, 2008,133:670-707.
  • 3Ayala TH,Schulman SP. Pathogenesis and early management of non-ST-segment elevation acute coronary syndromes. Cardiol Clin, 2006,24(1): 19-35.
  • 4Wu TG,Zhao Q,Huang WG,et al. Effect of intracoronary tiromban in patients undergoing percutaneous coronary intervention for acute coronary syndrom. Circ,2008, (72):1605-1609.
  • 5Badimona L,Vilahur G, Coronary atherothrombotic disease progress in antiplatelet therapy. Rev Esp Cardiol,2008,61 (5): 501-513.
  • 6Deckelbaum LI,Sax FL, Grossman W. Tirofiban, a nonpeptide inhibit or of the platelet glycoprotein Ⅱ b/Ⅲa receptors//Sasahara AA, Loscalzo J. New therapeutic agents in thrombosis and thrombolysis. New York:Marcel Dekker, 1997:355-365.
  • 7Furman MI,Krueger LA,Linden MD,et al. GPⅡb-Ⅲa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Thromb Haemost,2005,3(2):312-320.
  • 8Schwartz LB. Monoclonal antibodies against human mast cell tryptase demonstrate shared antigenic sites on subunits of tryptase and selective localization of the enzyme to mast cells[J].J Immunol, 1985,134(1):526-531.
  • 9Schwartz LB, Atkins PC, Bradford TR, et al. Release of tryptase together with histamine during the immediate cutaneous response to allergen[J]. J Allergy Clin Immunol, 1987,80(6) : 850-855.
  • 10Cairns JA, Walls AF. Mast cell tryptase is a mitogen for epithelial cells: stimulation of IL-8 production and intercellular adhesion molecule-1 expression [J]. J Immunol, 1996,156( 1 ) : 275-283.

共引文献135

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部